[Federal Register Volume 85, Number 229 (Friday, November 27, 2020)]
[Notices]
[Page 76086]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26168]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with Betty B. Tong, Ph.D., National Institute of 
Diabetes and Digestive and Kidney Diseases, Technology Advancement 
Office, 12A South Drive Suite 3011, Bethesda, MD 20892; telephone: 301-
451-7836; email: <a href="/cdn-cgi/l/email-protection#65110a0b02072508040c094b0b0c0d4b020a13"><span class="__cf_email__" data-cfemail="6c1803020b0e2c010d050042020504420b031a">[email protected]</span></a>. A signed Confidential Disclosure 
Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

P2Y14 Receptor Antagonists Containing A Biaryl Core

    The technology discloses composition of compounds that fully 
antagonize the human P2Y14 receptor, with moderate affinity with 
insignificant antagonism of other P2Y receptors. Therefore, they are 
highly selective P2Y14 receptor antagonists. Even though there is no 
P2Y14 receptor modulators in clinical use currently, selective P2Y14 
receptor antagonists are sought as potential therapeutic treatments for 
asthma, cystic fibrosis, inflammation and possibly diabetes and 
neurodegeneration.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

    Development of P2Y14 receptor antagonist for treatment of 
disorders, such as:
<bullet> Inflammation
<bullet> diabetes
<bullet> cystic fibrosis
<bullet> asthma
<bullet> neurodegeneration

Development Stage:

<bullet> Early stage
    Inventors: Kenneth A. Jacobson (NIDDK), Jinha Yu (NIDDK), Antonella 
Ciancetta (NIDDK), Zhiwei Wen (NIDDK), Young-Hwan Jung (NIDDK)
    Publications: Yu J, Ciancetta A, Dudas S, et al., Structure-guided 
modification of heterocyclic antagonists of the P2Y14 receptor. J. Med. 
Chem., 2018, 61: 4860-4882, Jung YH, Yu J, Wen Z, et al., Exploration 
of alternative scaffolds for P2Y14 receptor antagonists containing a 
biaryl core. J. Med. Chem., 2020, 63:9563-9589.
    Intellectual Property: HHS Reference No. E-028-2018-0/1, US 
Provisional Patent Application 62/628,699 filed 09 Feb 2018, 
International Patent Application PCT/US2019/17422, filed 11 Feb 2019.
    Licensing Contact: Betty B. Tong, Ph.D.; 301-451-7836; 
<a href="/cdn-cgi/l/email-protection#e0948f8e8782a08d81898cce8e8988ce878f96"><span class="__cf_email__" data-cfemail="e69289888184a68b878f8ac8888f8ec8818990">[email protected]</span></a>. This notice is made in accordance with 35 U.S.C. 
209 and 37 CFR part 404.

    Dated: November 19, 2020.
Bei Tong,
Senior Licensing and Patenting Manager, National Institute of Diabetes 
and Digestive and Kidney Diseases, Technology Advancement Office.
[FR Doc. 2020-26168 Filed 11-25-20; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>